- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
- 10-K Annual report
- 2.8 Agreement and Plan of Merger
- 10.63 Change In Control Agreement
- 10.64 Change-in-control Agreement
- 10.65 Change-in-control Agreement
- 10.66 Amended and Restated Change-in-control Agreement
- 10.67 Amended and Restated Change-in-control Agreement
- 10.68 Amended and Restated Chage-in-control Agreement
- 10.69 Amended and Restated Change-in-control Agreement
- 10.70 Restated Stock Agreement
- 10.71 Restricted Stock Agreement
- 14.1 Invitrogen Protocol
- 21.1 List of Subsidiaries
- 23.1 Consent of Ernst & Young, LLP
- 31.1 Certification of Chief Executive Officer
- 31.2 Certification of Chief Financial Officer
- 32.1 Certification of Chief Executive Officer
- 32.2 Certification of Chief Financial Officer
Exhibit 32.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER
I, C. Eric Winzer, Chief Financial Officer of Invitrogen Corporation (the “Registrant”), do hereby certify in accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:
(1) the AnnualReport on Form 10-K of the Registrant, to which this certification is attached as an exhibit (the “Report”), fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.
Dated: February 25, 2004 | /s/ C. Eric Winzer | |||||||
C. Eric Winzer Chief Financial Officer |
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Invitrogen and will be retained by Invitrogenand furnished to the Securities and Exchange Commission or its staff upon request.